Real-world treatment of patients with severe congenital protein C deficiency with protein C concentrate: A physician survey

Real-world treatment of patients with severe congenital protein C deficiency with protein C concentrate: A physician survey

Introduction: Replacement therapy with intravenous (IV) protein C concentrate (Ceprotin®; Baxalta US Inc., a Takeda company, Lexington, MA, USA; Takeda Manufacturing Austria AG, Vienna, Austria) is an approved treatment approach for patients with severe congenital protein C deficiency (SCPCD). Data...

Full description

Bibliographic Details
Main Authors: Michael Wang, Hans-Jörg Hertfelder, Elyse Swallow, Alexandra Greatsinger, Emma Billmyer, Samson Fung, Peter L. Turecek, Hanna T. Gazda, Csaba Siffel
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Thrombosis Update
Subjects:
Physician survey
Prophylaxis
Protein C concentrate
Severe congenital protein C deficiency
Subcutaneous
Online Access:http://www.sciencedirect.com/science/article/pii/S2666572724000014

Internet

http://www.sciencedirect.com/science/article/pii/S2666572724000014

Similar Items